Evaluation of Renal Angioplasty on Atherosclerotic Stenosis Since 2010
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 80
- 试验地点
- 1
- 主要终点
- Composite endpoint at 3 years
研究概览
简要总结
The interest of renal angioplasty in the nosological framework of atherosclerotic stenosis has been significantly challenged by STAR and ASTRAL clinical trials in 2009, confirmed by the CORAL study in 2014.
These studies did not show any benefit of the gesture on renal function, morbidity and cardiovascular mortality or the tension control. The aim of the study is to evaluate renal angioplasty on atherosclerotic stenosis.
详细描述
Previous studies did not concern the indication of renal angioplasty in some high-risk situations, such as malignant or resistant renal vascular hypertension, OAP (Acute pulmonary oedema) flash or acute renal failure of ischemic origin.
There is no work in the literature that has studied retrospectively the evolution of angioplasty practices renal artery disease on atherosclerotic stenosis since 2009, nor their remote results of the gesture.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •OAP flash: hospitalization for Acute congestive heart failure without any other identified etiology than renal artery stenosis
- •Resistant arterial hypertension under treatment including a diuretic
- •Acute renal failure or ischemic renal failure quickly progressive
- •Radiological criteria: renal ischemia visualized at arterial time of angio-CT or renal angio-MRI
排除标准
- •Renal transplant patients
- •Patients with another etiology of secondary hypertension, including fibro-muscular dysplasia of renal artery
- •Restenosis on stent, angioplasty of accessory renal artery
- •Patients subject to legal protection (safeguard of justice, guardianship) and persons deprived of liberty
- •Patients objecting to participate to the study
结局指标
主要结局
Composite endpoint at 3 years
时间窗: The inclusion day
Composite endpoint at 3 years : * Cardiovascular or renal mortality, * Initiation of a renal replacement therapy or estimated glomerular filtration rate decrease of more than 50%, Cardiovascular morbidity: hospitalization for congestive heart failure, myocardial infarction, myocardium, stroke.
次要结局
未报告次要终点